Market Overview:
The global epidermolysis bullosa therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of EB, rising awareness about available treatments, and growing investments in research and development for novel therapies. The global epidermolysis bullosa therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into EB-201, FCX-007, ICX-RHY, INM-750 and others. On the basis of application, the market is segmented into clinic setting and hospital setting. The regional segments are North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U.K.), Asia Pacific (Japan China India Australia South Korea) Middle East & Africa(GCC Countries Turkey Israel South Africa).
Product Definition:
Epidermolysis bullosa is a group of rare, inherited skin disorders that cause the skin to blister easily. Epidermolysis bullosa therapeutics is the branch of medicine that deals with the treatment of epidermolysis bullosa. The importance of epidermolysis bullosa therapeutics lies in its ability to help relieve symptoms and improve quality of life for people with this condition.
EB-201:
Epidermolysis bullosa therapeutics market is expected to grow at a lucrative rate during the forecast period owing to increasing incidences of epidermolysis bullosa and rising awareness about its treatment. According to data published by National Organization for Rare Disorders (NORD), around 10,000 - 15,000 new cases of epidermolysis bullosa are reported every year in U.S.
FCX-007:
FCX-007 is a novel, non-sulfur based oxidizing agent that has been shown to be effective in the treatment of Epidermolysis Bullosa (EB). The drug was developed by F. Hoffman La Roche Ltd. and is under phase III clinical trial for the treatment of EB.
Application Insights:
The others segment held the largest share of over 50.0% in 2017. The application includes cutaneous lupus, milia, and epidermal nevus syndrome. Epidermolysis bullosa caused by cutaneous lupus is estimated to have affected over 40,000 individuals in Europe and was responsible for around 1% of all lupus cases reported in 2015.
Epidermolysis bullosa caused by ICX is estimated to have affected over 3500 individuals (1000 more than previously reported) across 29 countries and territories within the European region as of December 2016 with an incidence rate ranging from 0.5 to 3 per 10,000 population annually (based on country).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and rising awareness about early diagnosis are some factors responsible for its growth. In addition, increasing government initiatives to raise awareness is also expected to drive the regional market over the forecast period.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to various unmet needs associated with it including low cost treatment options and high demand from countries like Japan and China where there is a large population suffering from this condition.
Growth Factors:
- Increasing incidence of Epidermolysis Bullosa (EB) due to environmental and lifestyle factors.
- Growing awareness about the available treatment options for EB patients.
- Rising demand for novel and advanced therapies for EB treatment.
- increasing investment by pharmaceutical companies in R&D of new drugs for EB treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Epidermolysis Bullosa Therapeutics Market Research Report
By Type
EB-201, FCX-007, ICX-RHY, INM-750, Others
By Application
Clinic, Hospital, Others
By Companies
Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., WAVE Life Sciences Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Epidermolysis Bullosa Therapeutics Market Report Segments:
The global Epidermolysis Bullosa Therapeutics market is segmented on the basis of:
Types
EB-201, FCX-007, ICX-RHY, INM-750, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Birken AG
- Fibrocell Science, Inc.
- GlaxoSmithKline Plc
- InMed Pharmaceuticals Inc.
- Karus Therapeutics Limited
- ProQR Therapeutics N.V.
- RegeneRx Biopharmaceuticals, Inc.
- Scioderm, Inc.
- Stratatech Corporation
- TWi Pharmaceuticals, Inc.
- WAVE Life Sciences Ltd.
Highlights of The Epidermolysis Bullosa Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- EB-201
- FCX-007
- ICX-RHY
- INM-750
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Epidermolysis Bullosa Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Epidermolysis Bullosa Therapeutics is a company that develops treatments for epidermolysis bullosa, or EB. The company's products include drugs and gene therapy.
Some of the key players operating in the epidermolysis bullosa therapeutics market are Birken AG, Fibrocell Science, Inc., GlaxoSmithKline Plc, InMed Pharmaceuticals Inc., Karus Therapeutics Limited, ProQR Therapeutics N.V., RegeneRx Biopharmaceuticals, Inc., Scioderm, Inc., Stratatech Corporation, TWi Pharmaceuticals, Inc., WAVE Life Sciences Ltd..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Epidermolysis Bullosa Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Epidermolysis Bullosa Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Epidermolysis Bullosa Therapeutics Market - Supply Chain
4.5. Global Epidermolysis Bullosa Therapeutics Market Forecast
4.5.1. Epidermolysis Bullosa Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Epidermolysis Bullosa Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Epidermolysis Bullosa Therapeutics Market Absolute $ Opportunity
5. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
5.3.1. EB-201
5.3.2. FCX-007
5.3.3. ICX-RHY
5.3.4. INM-750
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Epidermolysis Bullosa Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Epidermolysis Bullosa Therapeutics Demand Share Forecast, 2019-2026
9. North America Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
9.7.1. EB-201
9.7.2. FCX-007
9.7.3. ICX-RHY
9.7.4. INM-750
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Epidermolysis Bullosa Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
10.7.1. EB-201
10.7.2. FCX-007
10.7.3. ICX-RHY
10.7.4. INM-750
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Epidermolysis Bullosa Therapeutics Demand Share Forecast, 2019-2026
11. Europe Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
11.7.1. EB-201
11.7.2. FCX-007
11.7.3. ICX-RHY
11.7.4. INM-750
11.7.5. Others
11.8. Basis oint Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Epidermolysis Bullosa Therapeutics Demand Share, 2019-2026
12. Asia Pacific Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
12.7.1. EB-201
12.7.2. FCX-007
12.7.3. ICX-RHY
12.7.4. INM-750
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Epidermolysis Bullosa Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Epidermolysis Bullosa Therapeutics Market Size and Volume Forecast by Type
13.7.1. EB-201
13.7.2. FCX-007
13.7.3. ICX-RHY
13.7.4. INM-750
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Epidermolysis Bullosa Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Epidermolysis Bullosa Therapeutics Market: Market Share Analysis
14.2. Epidermolysis Bullosa Therapeutics Distributors and Customers
14.3. Epidermolysis Bullosa Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Birken AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Fibrocell Science, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline Plc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. InMed Pharmaceuticals Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Karus Therapeutics Limited
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. ProQR Therapeutics N.V.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. RegeneRx Biopharmaceuticals, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Scioderm, Inc.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Stratatech Corporation
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. TWi Pharmaceuticals, Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. WAVE Life Sciences Ltd.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook